#### (62) Valerie Miké and Kenneth E Stanley (eds) (1982) Statistics in Medical Research: Methods and Issues, with Applications in Cancer Research New York: John Wiley and Sons

#### Preamble

The book is dedicated to the memory of Jerome Cornfield and was published in the Wiley series in probability and mathematical statistics. In the frontispiece there is a quotation from Lewis Thomas, "From here on, as far ahead as one can see, medicine must be building, as a central part of its scientific base, a sold underpinning of statistical knowledge. Hunches and intuitive impressions are essential for getting the work started, but it is only through the quality of the numbers at the end that the truth can be told."

#### Aims

There is a growing need in medical research for the contributions of professionals trained in biostatistics and epidemiology, and there is a nationwide shortage of adequate manpower. The subject was discussed at length in the course of a workshop on epidemiology and biostatistics organized by the National Cancer Institute in 1979. Since there are not enough professionals in these fields to meet the needs of medical schools and cancer centers around the country, the recommendation was made that special seminars and teaching materials be developed to enhance the effectiveness of individuals now filling many of the positions. In response to the general recommendation a summer conference on statistics in cancer research was held at Memorial Sloan-Kettering Cancer Center during the week of June 22-26, 1981. This book is based on the lectures and discussions presented at the conference. The book offers a comprehensive overview of the field of biostatistics. Although the emphasis of the meeting was on cancer research, nearly everything discussed is applicable to other areas of medical investigation. Since there are currently many opportunities in biostatistics, this volume can provide useful information for classically trained statisticians interested in entering the field, and it can help those new to the field to become more effective collaborators. It can serve as stimulus for graduate students in statistics, to nurture their interest and to prepare them for careers in biostatistics. It can also be read with benefit by clinical investigators seeking a better understanding of statistical concepts and related multidisciplinary aspects of medical research (Preface, pages is and x).

#### Contents (xxi + 551 pages)

[Sub-sub-headings omitted] Preface (Valerie Miké, Kenneth E Stanley) Part I Introduction The role of statistics in medical research (Frederick Mosteller) 1. Importance of variance Problem formulation Design of investigations Nonsampling errors Analysis Reporting Schools of thought Tabulation To sum up References Part II Epidemiology

- 2. Cancer epidemiology (Theodore Colton, E Robert Greenberg) Introduction Descriptive epidemiology Ecologic relationships Analytic epidemiology Cohort studies Case-control studies Association to causation Appendix 1. Questions for assessment of a cohort study Appendix 2. Questions for assessment of a case-control study Appendix 3. Requirements for establishing causation from analytic observational studies References Bibliography
- Trends in cancer mortality and incidence in the United States: is the future clear or clouded? (Marvin A Schneiderman)
   Introduction
   Materials and methods
   Results
   Discussion
   References

Part III Issues in clinical studies

- 4. Clinical studies in cancer: a historical perspective (Valerie Miké) Early history of medicine The nineteenth century The twentieth century The cancer program today Accomplishments and future goals The impact of statistical methodology Major problems Conclusion References
- 5. Clinical trials: exploring ethical, legal, and psychological issues panel discussion (Valerie Miké, George J Annas, Eric J Cassell, Jimmie CB Holland, Robert J Levine) Legal aspects of clinical trials Psychological aspects of clinical trials Ethical aspects of clinical trials The physician-patient relationship Side effects versus benefits of chemotherapy Phase I trials and the terminal patient Social classes and clinical research Personal savings for experimental treatment Federal regulations: legal and ethical? Randomized trials and the new federal guidelines Concluding remarks References Nuremburg code

Declaration of Helsinki

6. Issues in the design of clinical trials – panel discussion (John C Bailar III, Byron W Brown, Jerome J DeCosse, Edmund A Gehan, James F Holland)

Views of a medical oncologist The issues as seen by a statistician Views of a surgical oncologist A statistician responds The osteogenic sarcoma controversy The case for randomisation in clinical trials Patient acceptance of randomisation Differences in quality of historical controls The need for a balanced view Sequential designs Concluding remarks References Part IV Practical considerations 7. Design and implementation of clinical trials (Martin L Lesser) Types of clinical trials and their structure Sample size and power determination Implementation of clinical trials References 8. Data management and quality control (Judith R O'Fallon) Introduction Data item selection Forms design and testing Data collection: personnel, materials, procedures Data editing procedures Monitoring data quality Development of reports Other procedures associated with data management Discussion References 9. Statistical software, data base management, statistical packages, and graphics (David W Brown Jr) Introduction

Using a computer system Statistical packages Data base management systems FORTRAN program libraries Summary Bibliography Appendix 1. SAS Appendix 2. SPSS Appendix 3. BMDP Appendix 4. Minitab Appendix 5. P-STAT Appendix 6. OSIRIS IV Appendix 7. SIR Appendix 8. IMSL Appendix 9. NCAR Appendix 10. GR-Z Part V Statistical methodology

- Estimation in survival analysis: parametric models, product-limit and life-table methods (Byron W Brown Jr) References Bibliography
- 11. Inference in survival analysis: nonparametric tests to compare survival distributions (Stephen W Lagakos) Introduction Preliminaries A family of nonparametric tests Derivations of tests from Cox's regression model Properties of tests Extensions
  - Summary
  - References
- 12. Analysis of survival data: Cox and Weibull models with covariates (David P Byar) Introduction
  - Screening for prognostic significance
  - Survival models incorporating covariates
  - Fitting interaction terms
  - Conclusions
  - References
- 13. Analysis of categorical data: exact tests and log-linear models (Thomas A Louis) Introduction
  - The  $2 \times 2$  table
  - Testing and confidence intervals (asymptotic methods)
  - Simpson's paradox
  - A problem with log-linear models
  - Residuals and parsimonious models
  - Model selection
  - Random effects models
  - Bradley-Terry model
  - Additional topics
  - Appendix. Fitting models
  - References
- 14. Analysis of categorical data: logistic models (David A Schoenfeld) Introduction Exact test for treatment or covariate effects
  - Exact test for treatment or covariate effects
  - Asymptotic tests for treatment effect
  - Interpreting the model
  - Coding variables
  - Variable selection techniques
  - Testing goodness of fit
  - Ordinal response data
  - References
- 15. Monitoring and stopping clinical trials (Mitchell H Gail) Introduction
  - Monitoring data on pairwise treatment differences
  - Criticisms and comparisons of proposed boundaries
  - Monitoring time to response data
  - Discussion

References

### Part VI Communication

16. Interacting with the medical community: consulting, collaboration, teaching - panel discussion (Theodore Colton, Edmund A Gehan, Lawrence E Hinkle Jr, Carl M Pinsky, Kenneth E Stanley)

Role of the biostatistician Working as equals

- Aspects of consulting
- Professional interchange
- Responsibility and collaboration

Who should pay?

- Authorship
- Evaluating the role of others
- Physicians' view of a good statistician
- The need for specialized assistance
- Physical proximity: pros and cons
- Meeting deadlines
- Facing tradition
- Educating physicians
- Educating statisticians
- A difference in perspective
- The Institutional Review Board
- References
- 17. Interpretation and presentation of statistical results panel discussion (Kenneth E Stanley, David P Byar, Mitchell H Gail, Richard D Gelber, Paul P Rosen) Conflicting goals The pathologists' perspective Preparing the written report The statistician as skeptic Factors affecting quality Reporting details of study design Comparability of data sets Other issues: sample size and exclusion of ineligible cases Reporting power; protocol violation and missing data Patient refusal and selection bias **Reporting results** Describing analytic models Retrospective analyses Potential bias in post hoc comparisons Time-dependent covariate analysis Concluding remarks Standardized reporting scheme for clinical trials

## Index

# Authors

References

The editors are Valerie Miké PhD (Head, Biostatistics Laboratory, Memorial Sloan-Kettering Cancer Center and Professor and Chairman of the Biostatistics Unit, Cornell University Graduate School of Medical Sciences, and Professor of Biostatistics in Public Health, Cornell

Publishing results of exploratory data analysis

University Medical College, New York, NY) and Kenneth E Stanley PhD (Assistant Professor of Biostatistics, Harvard University School of Public Health and the Sidney Farber Cancer Institute, Boston, MA). The contributors are George J Annas JD MPH (Department of Social Medical Sciences and Community Medicine, Boston University School of Public Health, Boston, MA); John C Bailar III, MD, PhD (US Environmental Protection Agency, Washington DC and Department of Biostatistics, Harvard University School of Public Health, Boston, MA); David W Braun Jr, PhD (Biostatistics Laboratory, Memorial Sloan-Kettering Cancer Center and Cornell University, New York, NY); Byron W Brown Jr, PhD (Division of Biostatistics, Stanford University School of Medicine, Stanford, CA); David P Byar MD (Biometry Branch, National Cancer Institute, Bethesda MD): Eric J Cassell MD (Department of Public Health, Cornell University Medical College, New York, NY); Theodore Colton ScD (Epidemiology and Biostatistics Section, Boston University School of Public Health and Hubert H Humphrey Cancer Center, Boston, MA); Jerome J DeCosse MD, PhD (Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY); Mitchell H Gail MD, PhD (Biometry Branch, National Cancer Institute, Bethesda, MD); Edmund A Gehan PhD (Department of Biomathematics, University of Texas System Cancer Center, Houston, Texas); Richard D Gelber PhD (Department of Biostatistics, Harvard University School of Public Health and Sidney Farber Cancer Institute, Boston, MA); E Robert Greenberg MD (Department of Community and Family Medicine, Dartmouth Medical School, Hanover, New Hampshire); Lawrence E Hinkle Jr MD (Department of Medicine, Cornell University Medical College, New York, NY); James F Holland MD (Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, NY); Jimmie CB Holland MD (Psychiatry Service, Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY); Stephen W Lagakos PhD (Department of Biostatistics, Harvard University School of Public Health and Sidney Farber Cancer Institute, Boston, MA); Martin L Lesser PhD (Biostatistics Laboratory, Memorial Sloan-Kettering Cancer Center and Cornell University, New York, NY); Robert J Levine MD (Department of Internal Medicine, Yale University, School of Medicine, New Haven, Connecticut): Thomas A Louis PhD (Department of Biostatistics, Harvard University School of Public Health, Boston, MA); Frederick Mosteller PhD (Department of Health Policy and Management, Harvard University School of Public Health, Boston, MA); Judith R O'Fallon PhD (Cancer Center Statistics, Mayo Comprehensive Cancer Center, Rochester, Minnesota); Carl M Pinsky MD (Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY); Paul P Rosen MD (Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY); Marvin A Schneiderman PhD (Clement Associates, Arlington, VA); and, David A Schoenfeld PhD (Department of Biostatistics, Harvard University School of Public Health, and Sidney Farber Cancer Institute, Boston, MA)